Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Nov;66(5):970–976. doi: 10.1038/bjc.1992.394

Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer.

G Gasparini 1, P Bevilacqua 1, F Pozza 1, S Meli 1, P Boracchi 1, E Marubini 1, J R Sainsbury 1
PMCID: PMC1978004  PMID: 1419645

Abstract

The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein whose expression is important in the regulation of breast cancer cell growth. The relationship between EGFR status (determined by an immunocytochemical assay) and various prognostic factors was investigated in 164 primary breast cancers. Overall 56% of tumours were EGFR-positive and the expression of EGFR was unrelated to axillary node status, tumour size and histological grade; and it was poorly associated with the tumour proliferative activity measured by Ki-67 immuno-cytochemistry. The relapse-free survival (RFS) probability at 3-years was significantly worse for patients with EGFR positive tumours (P = 0.003) and for those whose Ki-67 score was > 7.5% (P = 0.0027), as well as in patients with axillary node involvement (P = 0.01) and with poorly differentiated tumours (P = 0.04). Immunocytochemical determination of EGFR and cell kinetics gave superimposable prognostic information for predicting RFS with odds ratios of 3.51, when evaluated singly. In our series of patients EGFR, Ki-67 and node status retain their prognostic value concerning RFS in multivariate analysis. The 3-year probability of overall survival (OS) was significantly better in node-negative patients (P = 0.04) and was similar in EGFR-positive and negative patients. In conclusion, EGFR status appears to be a significant and independent indicator of recurrence in human breast cancer and the concomitant measurement of the tumour proliferative activity seems to improve the selection of patients with different risks of recurrence.

Full text

PDF
970

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bevilacqua P., Gasparini G., Dal Fior S., Corradi G. Immunocytochemical determination of epidermal growth factor receptor with monoclonal EGFR1 antibody in primary breast cancer patients. Oncology. 1990;47(4):313–317. doi: 10.1159/000226840. [DOI] [PubMed] [Google Scholar]
  3. Blamey R. The 1989 Walter Hubert lecture. Does biological understanding influence surgical practice? Br J Cancer. 1989 Sep;60(3):271–274. doi: 10.1038/bjc.1989.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bonadonna G. Adjuvant chemotherapy in node-negative breast cancer. NCI consensus conference. Eur J Cancer. 1990;26(7):844–845. doi: 10.1016/0277-5379(90)90168-s. [DOI] [PubMed] [Google Scholar]
  5. Chan P. K., Frakes R., Tan E. M., Brattain M. G., Smetana K., Busch H. Indirect immunofluorescence studies of proliferating cell nuclear antigen in nucleoli of human tumor and normal tissues. Cancer Res. 1983 Aug;43(8):3770–3777. [PubMed] [Google Scholar]
  6. Charpin C., Andrac L., Vacheret H., Habib M. C., Devictor B., Lavaut M. N., Toga M. Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections. Cancer Res. 1988 Aug 1;48(15):4368–4374. [PubMed] [Google Scholar]
  7. Cox B. G. The author's editor. Mayo Clin Proc. 1974 May;49(5):314–317. [PubMed] [Google Scholar]
  8. Dexter D. L., Kowalski H. M., Blazar B. A., Fligiel Z., Vogel R., Heppner G. H. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res. 1978 Oct;38(10):3174–3181. [PubMed] [Google Scholar]
  9. Fisher B., Ravdin R. G., Ausman R. K., Slack N. H., Moore G. E., Noer R. J. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg. 1968 Sep;168(3):337–356. doi: 10.1097/00000658-196809000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fisher E. R., Gregorio R. M., Fisher B., Redmond C., Vellios F., Sommers S. C. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer. 1975 Jul;36(1):1–85. doi: 10.1002/1097-0142(197507)36:1<1::aid-cncr2820360102>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  11. Fitzpatrick S. L., LaChance M. P., Schultz G. S. Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture. Cancer Res. 1984 Aug;44(8):3442–3447. [PubMed] [Google Scholar]
  12. Foekens J. A., Portengen H., van Putten W. L., Trapman A. M., Reubi J. C., Alexieva-Figusch J., Klijn J. G. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res. 1989 Dec 15;49(24 Pt 1):7002–7009. [PubMed] [Google Scholar]
  13. Freeman J. W., Busch R. K., Gyorkey F., Gyorkey P., Ross B. E., Busch H. Identification and characterization of a human proliferation-associated nucleolar antigen with a molecular weight of 120,000 expressed in early G1 phase. Cancer Res. 1988 Mar 1;48(5):1244–1251. [PubMed] [Google Scholar]
  14. Gasparini G., Dal Fior S., Pozza F., Bevilacqua P. Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma. Breast Cancer Res Treat. 1989 Dec;14(3):329–336. doi: 10.1007/BF01806305. [DOI] [PubMed] [Google Scholar]
  15. Gasparini G., Reitano M., Bevilacqua P., Meli S., Pozza F., Santini G. Relationship of the epidermal growth factor-receptor to the growth fraction (Ki-67 antibody) and the flow cytometric S-phase as cell kinetics parameters, in human mammary carcinomas. Anticancer Res. 1991 Jul-Aug;11(4):1597–1603. [PubMed] [Google Scholar]
  16. Gerdes J., Lemke H., Baisch H., Wacker H. H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984 Oct;133(4):1710–1715. [PubMed] [Google Scholar]
  17. Hedley D. W., Rugg C. A., Gelber R. D. Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res. 1987 Sep 1;47(17):4729–4735. [PubMed] [Google Scholar]
  18. Heldin C. H., Westermark B. Growth factors: mechanism of action and relation to oncogenes. Cell. 1984 May;37(1):9–20. doi: 10.1016/0092-8674(84)90296-4. [DOI] [PubMed] [Google Scholar]
  19. Hsu S. M., Raine L., Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 1981 May;75(5):734–738. doi: 10.1093/ajcp/75.5.734. [DOI] [PubMed] [Google Scholar]
  20. Isola J. J., Helin H. J., Helle M. J., Kallioniemi O. P. Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer. 1990 Mar 1;65(5):1180–1184. doi: 10.1002/1097-0142(19900301)65:5<1180::aid-cncr2820650525>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  21. Kalofonos H. P., Pawlikowska T. R., Hemingway A., Courtenay-Luck N., Dhokia B., Snook D., Sivolapenko G. B., Hooker G. R., McKenzie C. G., Lavender P. J. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med. 1989 Oct;30(10):1636–1645. [PubMed] [Google Scholar]
  22. Koenders P. G., Beex L. V., Geurts-Moespot A., Heuvel J. J., Kienhuis C. B., Benraad T. J. Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res. 1991 Sep 1;51(17):4544–4548. [PubMed] [Google Scholar]
  23. Lewis S., Locker A., Todd J. H., Bell J. A., Nicholson R., Elston C. W., Blamey R. W., Ellis I. O. Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol. 1990 May;43(5):385–389. doi: 10.1136/jcp.43.5.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lippman M. E., Dickson R. B., Bates S., Knabbe C., Huff K., Swain S., McManaway M., Bronzert D., Kasid A., Gelmann E. P. 8th San Antonio Breast Cancer Symposium--Plenary lecture. Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat. 1986;7(2):59–70. doi: 10.1007/BF01806790. [DOI] [PubMed] [Google Scholar]
  25. Macias A., Azavedo E., Hägerström T., Klintenberg C., Pérez R., Skoog L. Prognostic significance of the receptor for epidermal growth factor in human mammary carcinomas. Anticancer Res. 1987 May-Jun;7(3 Pt B):459–464. [PubMed] [Google Scholar]
  26. McGuire W. L. Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat. 1987 Oct;10(1):5–9. doi: 10.1007/BF01806129. [DOI] [PubMed] [Google Scholar]
  27. Neal D. E., Marsh C., Bennett M. K., Abel P. D., Hall R. R., Sainsbury J. R., Harris A. L. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet. 1985 Feb 16;1(8425):366–368. doi: 10.1016/s0140-6736(85)91386-8. [DOI] [PubMed] [Google Scholar]
  28. Nicholson S., Richard J., Sainsbury C., Halcrow P., Kelly P., Angus B., Wright C., Henry J., Farndon J. R., Harris A. L. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer. 1991 Jan;63(1):146–150. doi: 10.1038/bjc.1991.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Pekonen F., Partanen S., Mäkinen T., Rutanen E. M. Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res. 1988 Mar 1;48(5):1343–1347. [PubMed] [Google Scholar]
  30. Peyrat J. P., Bonneterre J., Vandewalle B., Djiane J., Lefebvre J. Récepteurs de l'EGF dans les cancers du sein humains. Relations avec les récepteurs hormonaux. Ann Endocrinol (Paris) 1984;45(6):412–413. [PubMed] [Google Scholar]
  31. Roos W., Fabbro D., Küng W., Costa S. D., Eppenberger U. Correlation between hormone dependency and the regulation of epidermal growth factor receptor by tumor promoters in human mammary carcinoma cells. Proc Natl Acad Sci U S A. 1986 Feb;83(4):991–995. doi: 10.1073/pnas.83.4.991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sainsbury J. R., Farndon J. R., Needham G. K., Malcolm A. J., Harris A. L. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987 Jun 20;1(8547):1398–1402. doi: 10.1016/s0140-6736(87)90593-9. [DOI] [PubMed] [Google Scholar]
  33. Sainsbury J. R., Farndon J. R., Sherbet G. V., Harris A. L. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet. 1985 Feb 16;1(8425):364–366. doi: 10.1016/s0140-6736(85)91385-6. [DOI] [PubMed] [Google Scholar]
  34. Salomon D. S., Zwiebel J. A., Bano M., Losonczy I., Fehnel P., Kidwell W. R. Presence of transforming growth factors in human breast cancer cells. Cancer Res. 1984 Sep;44(9):4069–4077. [PubMed] [Google Scholar]
  35. Silvestrini R., Daidone M. G., Gasparini G. Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer. 1985 Oct 15;56(8):1982–1987. doi: 10.1002/1097-0142(19851015)56:8<1982::aid-cncr2820560816>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  36. Spyratos F., Delarue J. C., Andrieu C., Lidereau R., Champème M. H., Hacène K., Brunet M. Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat. 1990 Dec;17(2):83–89. doi: 10.1007/BF01806288. [DOI] [PubMed] [Google Scholar]
  37. Stoscheck C. M., King L. E., Jr Role of epidermal growth factor in carcinogenesis. Cancer Res. 1986 Mar;46(3):1030–1037. [PubMed] [Google Scholar]
  38. Toi M., Osaki A., Yamada H., Toge T. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer. 1991;27(8):977–980. doi: 10.1016/0277-5379(91)90262-c. [DOI] [PubMed] [Google Scholar]
  39. Tubiana M., Pejovic M. H., Chavaudra N., Contesso G., Malaise E. P. The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer. 1984 Apr 15;33(4):441–445. doi: 10.1002/ijc.2910330404. [DOI] [PubMed] [Google Scholar]
  40. Walker R. A., Camplejohn R. S. DNA flow cytometry of human breast carcinomas and its relationship to transferrin and epidermal growth factor receptors. J Pathol. 1986 Sep;150(1):37–42. doi: 10.1002/path.1711500107. [DOI] [PubMed] [Google Scholar]
  41. Waterfield M. D., Mayes E. L., Stroobant P., Bennet P. L., Young S., Goodfellow P. N., Banting G. S., Ozanne B. A monoclonal antibody to the human epidermal growth factor receptor. J Cell Biochem. 1982;20(2):149–161. doi: 10.1002/jcb.240200207. [DOI] [PubMed] [Google Scholar]
  42. Wright C., Angus B., Nicholson S., Sainsbury J. R., Cairns J., Gullick W. J., Kelly P., Harris A. L., Horne C. H. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989 Apr 15;49(8):2087–2090. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES